Biotech Capital

About The Fund

Biotech Capital, trading as BTC Health Ltd, is a pooled development fund listed on the Australian Stock Exchange. With a focus on the life sciences sector, they offer first-class medical and health solutions by investing in, selling, marketing, and distributing cutting-edge specialized medical products. Their investment strategy involves targeting opportunities related to biotechnology, life sciences, and healthcare with an investment range between $1,300,000 and $80,400,000. Through a portfolio of subsidiaries, such as BTC Specialty Health, BTC Pharma, and BTC Cardio, they tackle various market segments, including acute pain management, neuro-spinal, cardiovascular, and pharmaceuticals. They are a leader in elastomeric and electronic infusion pumps for post-operative pain management and regional anaesthesia, and they supply a broad array of products like tissue and bone biopsy needles, bone cement injectors, pedicle access kits, radiological markers, and cardiovascular medical equipment. BTC Health also offers specialized pharmaceuticals for rare diseases and niche medical conditions. They maintain a national footprint in Australia and New Zealand, operating out of seven ISO-certified warehouses that serve private and public hospitals with high service levels. Their team of national business managers possesses deep industry experience, focusing on educational support and customer relationships to ensure commitment at all care levels. BTC Health's robust Quality Management Systems and extensive capabilities in regulatory matters, reimbursement, and state health tenders support all business aspects. Furthermore, they emphasize a partnering philosophy that seeks to optimize commercial outcomes for third-party suppliers by tailoring strategies to individual products and ensures trust, integrity, and a customer-centric approach. BTC Health's investments demonstrate their commitment to their sector, with stakes in companies specializing in different areas of healthcare technology and solutions, further solidifying them as a significant player in the healthcare investment space in the Australasian market.